Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
Given concerns about radiation dose and a call for more comfortable machines, officials at Philips saw an opportunity for a new product in the North American mammography market. Last week Philips introduced their MicroDose Mammography system, which officials said provides a lower dose, less stressful scan.
“The U.S. is in the process of turning over the generation one machines to a purchase cycle, so we believe this is the perfect product” for the market, said Pam Benkert, general manager, women’s healthcare for Philips Healthcare. “We wanted a differentiated offering.”
MicroDose is the only FDA-cleared mammography system to use X-ray photon counting technology. The detector captures almost every photon that travels from the source to the breast to the detector, Benkert explained. There’s very little scatter, which allows for an up to 50 percent dose reduction, she said.
The machine also has curved support and a warm position surface, intended to make it more comfortable for the patient, she said.
The product, she said, is “uniquely suited to the population” in North America.
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.